- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Howtek sales drop prompts layoffs
A sharp decline in sales at x-ray film digitizer firm Howtek hasforced the Hudson, NH, company to cut 20 jobs. Howtek attributedthe revenue shortfall to delays in getting Food and Drug Administrationclearance for its Scanmaster DX product. The FDA
A sharp decline in sales at x-ray film digitizer firm Howtek hasforced the Hudson, NH, company to cut 20 jobs. Howtek attributedthe revenue shortfall to delays in getting Food and Drug Administrationclearance for its Scanmaster DX product. The FDA cleared the digitizerin January, three months after Howtek's planned launch date inNovember.
For the first quarter of 1996 (end-March), Howtek had salesof $2 million, a major drop from the $5.9 million in revenuesposted in the first quarter of 1995. The company registered aloss of $2.3 million, compared with net income of $153,000 inthe same quarter a year ago.
Howtek said that weakness in the graphic arts market, whereit also markets its scanners, also contributed to the shortfall.The company said that the layoffs are designed to get expensesback in line with revenues.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
